Literature DB >> 16983549

Outcome in bacteremia associated with nosocomial pneumonia and the impact of pathogen prediction by tracheal surveillance cultures.

Pieter Depuydt1, Dominique Benoit, Dirk Vogelaers, Geert Claeys, Gerda Verschraegen, Koenraad Vandewoude, Johan Decruyenaere, Stijn Blot.   

Abstract

OBJECTIVE: To assess whether pathogen prediction in bacteremia associated with nosocomial pneumonia (NP) by tracheal surveillance cultures improves adequacy of early antibiotic therapy and impacts mortality. DESIGN AND
SETTING: A retrospective observational study of a prospectively gathered cohort. This cohort included all adult patients admitted to the ICU of a tertiary care hospital from 1992 through 2001 and who developed bacteremia associated with NP.
MEASUREMENTS AND MAIN RESULTS: 128 episodes of bacteremia associated with NP were identified. In 110 episodes a tracheal surveillance culture 48-96h prior to bacteremia was available: this culture predicted the pathogen in 67 episodes (61%). Overall rates of appropriate empiric antibiotic therapy within 24 and 48h were 62 and 87%, respectively. Pathogen prediction was associated with a significantly higher rate of appropriate antibiotic therapy within 24h (71 vs 45%; p=0.01), but not within 48h (91 vs 82%; p=0.15). Crude in-hospital mortality was 50%. Pathogen prediction was associated with increased survival in univariate (OR 0.43; CI 0.19-0.93; p=0.04) and multivariate analysis (OR 0.32; CI 0.12-0.82; p=0.02). Multivariate analysis further identified age (OR 1.04; CI 1.01-1.07; p=0.02), increasing APACHEII score (OR 1.08; CI 1.02-1.15; p=0.01), and methicillin-resistant Staphylococcus aureus (OR 5.90; CI 1.36-25.36; p=0.01) and Pseudomonas aeruginosa (OR 3.30; CI 1.04-10.4; p=0.04) as independent risk factors for mortality.
CONCLUSION: Pathogen prediction in bacteremia associated with NP by tracheal surveillance cultures is associated with a higher rate of adequate empiric antibiotic therapy within 24[Symbol: see text]h and with increased survival.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16983549     DOI: 10.1007/s00134-006-0354-8

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  44 in total

1.  Evaluation of outcome for intubated patients with pneumonia due to Pseudomonas aeruginosa.

Authors:  J Rello; P Jubert; J Vallés; A Artigas; M Rué; M S Niederman
Journal:  Clin Infect Dis       Date:  1996-11       Impact factor: 9.079

Review 2.  Appropriate and timely empirical antimicrobial treatment of icu infections--a role for carbapenems.

Authors:  F Colardyn
Journal:  Acta Clin Belg       Date:  2005 Mar-Apr       Impact factor: 1.264

Review 3.  Impact of antibiotic resistance on clinical outcomes and the cost of care.

Authors:  M S Niederman
Journal:  Crit Care Med       Date:  2001-04       Impact factor: 7.598

4.  Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents.

Authors:  Y Carmeli; N Troillet; G M Eliopoulos; M H Samore
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

5.  The influence of mini-BAL cultures on patient outcomes: implications for the antibiotic management of ventilator-associated pneumonia.

Authors:  M H Kollef; S Ward
Journal:  Chest       Date:  1998-02       Impact factor: 9.410

6.  Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients.

Authors:  M H Kollef; G Sherman; S Ward; V J Fraser
Journal:  Chest       Date:  1999-02       Impact factor: 9.410

7.  Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia.

Authors:  Richard G Wunderink; Jordi Rello; Sue K Cammarata; Rodney V Croos-Dabrera; Marin H Kollef
Journal:  Chest       Date:  2003-11       Impact factor: 9.410

Review 8.  Nosocomial infections in adult intensive-care units.

Authors:  Jean-Louis Vincent
Journal:  Lancet       Date:  2003-06-14       Impact factor: 79.321

9.  Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia.

Authors:  Manuel Iregui; Suzanne Ward; Glenda Sherman; Victoria J Fraser; Marin H Kollef
Journal:  Chest       Date:  2002-07       Impact factor: 9.410

10.  The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee.

Authors:  J L Vincent; D J Bihari; P M Suter; H A Bruining; J White; M H Nicolas-Chanoin; M Wolff; R C Spencer; M Hemmer
Journal:  JAMA       Date:  1995 Aug 23-30       Impact factor: 56.272

View more
  21 in total

Review 1.  Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis.

Authors:  Mical Paul; Vered Shani; Eli Muchtar; Galia Kariv; Eyal Robenshtok; Leonard Leibovici
Journal:  Antimicrob Agents Chemother       Date:  2010-08-23       Impact factor: 5.191

2.  Maximizing rates of empiric appropriate antibiotic therapy with minimized use of broad-spectrum agents: are surveillance cultures the key?

Authors:  S Blot; P Depuydt; D Vogelaers
Journal:  Intensive Care Med       Date:  2008-08-19       Impact factor: 17.440

3.  The role of surveillance cultures in the prediction of susceptibility patterns of Gram-negative bacilli in the intensive care unit.

Authors:  H Baba; G R Nimmo; A M Allworth; R J Boots; Y Hayashi; J Lipman; D L Paterson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-01-11       Impact factor: 3.267

Review 4.  Value of lower respiratory tract surveillance cultures to predict bacterial pathogens in ventilator-associated pneumonia: systematic review and diagnostic test accuracy meta-analysis.

Authors:  Nele Brusselaers; Sonia Labeau; Dirk Vogelaers; Stijn Blot
Journal:  Intensive Care Med       Date:  2012-11-28       Impact factor: 17.440

5.  Self-trimerization of ExsD limits inhibition of the Pseudomonas aeruginosa transcriptional activator ExsA in vitro.

Authors:  Robert C Bernhards; Anne E Marsden; Shannon K Esher; Timothy L Yahr; Florian D Schubot
Journal:  FEBS J       Date:  2013-01-24       Impact factor: 5.542

6.  Outcomes in critically ill chronic lymphocytic leukemia patients.

Authors:  Aliénor Xhaard; Loic Epelboin; David Schnell; François Vincent; Vincent Levy; Marion Malphettes; Elie Azoulay; Michaël Darmon
Journal:  Support Care Cancer       Date:  2013-02-15       Impact factor: 3.603

7.  De-escalation of antimicrobial treatment in neutropenic patients with severe sepsis: results from an observational study.

Authors:  Djamel Mokart; Géraldine Slehofer; Jérôme Lambert; Antoine Sannini; Laurent Chow-Chine; Jean-Paul Brun; Pierre Berger; Ségolène Duran; Marion Faucher; Jean-Louis Blache; Colombe Saillard; Norbert Vey; Marc Leone
Journal:  Intensive Care Med       Date:  2014-01       Impact factor: 17.440

8.  Systematic surveillance cultures as a tool to predict involvement of multidrug antibiotic resistant bacteria in ventilator-associated pneumonia.

Authors:  P Depuydt; D Benoit; D Vogelaers; J Decruyenaere; D Vandijck; G Claeys; G Verschraegen; S Blot
Journal:  Intensive Care Med       Date:  2007-12-08       Impact factor: 17.440

9.  Predictors of bacteraemia and mortality in patients with acute liver failure.

Authors:  Constantine J Karvellas; Fred Pink; Mark McPhail; Timothy Cross; Georg Auzinger; William Bernal; Elizabeth Sizer; Demetrios J Kutsogiannis; Ian Eltringham; Julia A Wendon
Journal:  Intensive Care Med       Date:  2009-04-03       Impact factor: 17.440

10.  Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.

Authors:  Tetsufumi Koga; Nobuhisa Masuda; Masayo Kakuta; Eiko Namba; Chika Sugihara; Takashi Fukuoka
Journal:  Antimicrob Agents Chemother       Date:  2008-06-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.